content

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

AbbVie and Harvard University announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop...

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Bristol Myers Squibb and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic...

BMS Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include...

Mitsubishi Tanabe Pharma Launch of VAFSEO,for the treatment of renal anemia in Japan

Mitsubishi Tanabe Pharma Corporation announced that MTPC is launchingVAFSEO®Tablets 150mg and 300mg (VAFSEO®, vadadustat) which is anoralhypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in-licensed from...

Thermo Fisher Scientific Introduces Hematology-Oncology Portfolio for Ion Torrent Genexus System

In hematology oncology, it is critically important to understand the genetics driving acute malignancies to quickly determine how best to address the disease. Today,...

Quanticate Announces new Partnership with Antev Ltd

Quanticate is pleased to partner with Antev Limited on a Phase II, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix...

UAEs Mubadala invests in US pharma business

Abu Dhabi’s sovereign wealth fund, Mubadala, and New York-based private equity group Kohlberg will take a majority stake in the pharmaceutical company PCI Pharma...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read